Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis

• NASDAQ: $ARQT
• Notified: $29.00
• 09:02 EDT